A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer

被引：0
|
作者：
Wu, Jiong
Zhang, Jian
Tong, Zhongsheng
Zhang, Qingyuan
Wang, Yong-Sheng
Cheng, Qiao
Chen, Xin
Li, Zhihua
Yin, Yongmei
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PS08-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS08-06
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
    Alessandra Fabi
    Luisa Carbognin
    Andrea Botticelli
    Ida Paris
    Paola Fuso
    Maria Cristina Savastano
    Nicla La Verde
    Carla Strina
    Rebecca Pedersini
    Stefania Guarino
    Giuseppe Curigliano
    Carmen Criscitiello
    Mimma Raffaele
    Alessandra Beano
    Antonio Franco
    Maria Rosaria Valerio
    Francesco Verderame
    Andrea Fontana
    Eva Regina Haspinger
    Alessia Caldara
    Alba Di Leone
    Giampaolo Tortora
    Diana Giannarelli
    Giovanni Scambia
    npj Breast Cancer, 10
  • [32] ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
    Cortes Salgado, A.
    Perez Garcia, J. M.
    Cortez Castedo, S. P.
    Gion Cortes, M.
    Morales Murillo, S.
    Blancas Lopez-Barajas, I.
    Blanch, S.
    Calvo Plaza, I.
    Diaz Fernandez, N.
    Marme, F.
    Martinez Bueno, A.
    Taberner Bonastre, M. T.
    De laurentiis, M.
    Ruiz Borrego, M.
    Schmid, P.
    Guarneri, V.
    Gligorov, J.
    Sampayo-Cordero, M.
    Llombart Cussac, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S221 - S221
  • [33] tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pier Franco
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Marc A.
    O'Shaughnessy, Joyce
    Li, Li
    Barton, Debora
    Beck, Robert M.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pierfranco F.
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Mark A.
    O'Shaughnessy, Joyce
    Beck, Robert M.
    Ko, Amy
    Renschler, Markus F.
    Barton, Debora
    Harbeck, Nadia
    TRIALS, 2015, 16
  • [35] Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Schmid, Peter
    Rugo, Hope S.
    Adams, Sylvia
    Schneeweiss, Andreas
    Barrios, Carlos H.
    Iwata, Hiroji
    Dieras, Veronique
    Henschel, Volkmar
    Molinero, Luciana
    Chui, Stephen Y.
    Maiya, Vidya
    Husain, Amreen
    Winer, Eric P.
    Loi, Sherene
    Emens, Leisha A.
    LANCET ONCOLOGY, 2020, 21 (01): : 44 - 59
  • [36] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    Denise A. Yardley
    Adam Brufsky
    Robert E. Coleman
    Pierfranco F. Conte
    Javier Cortes
    Stefan Glück
    Jean-Mark A. Nabholtz
    Joyce O’Shaughnessy
    Robert M. Beck
    Amy Ko
    Markus F. Renschler
    Debora Barton
    Nadia Harbeck
    Trials, 16
  • [37] Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
    Hirano, Hidekazu
    Takahashi, Naoki
    Amanuma, Yusuke
    Suzuki, Nobumi
    Takahari, Daisuke
    Kawakami, Takeshi
    Kudo-Saito, Chie
    Nagashima, Kengo
    Boku, Narikazu
    Kato, Ken
    Shoji, Hirokazu
    BMC CANCER, 2025, 25 (01)
  • [38] Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 73, 2023)
    Fabi, Alessandra
    Carbognin, Luisa
    Botticelli, Andrea
    Paris, Ida
    Fuso, Paola
    Savastano, Maria Cristina
    La Verde, Nicla
    Strina, Carla
    Pedersini, Rebecca
    Guarino, Stefania
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Raffaele, Mimma
    Beano, Alessandra
    Franco, Antonio
    Valerio, Maria Rosaria
    Verderame, Francesco
    Fontana, Andrea
    Haspinger, Eva Regina
    Caldara, Alessia
    Di Leone, Alba
    Tortora, Giampaolo
    Giannarelli, Diana
    Scambia, Giovanni
    NPJ BREAST CANCER, 2024, 10 (01)
  • [39] A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study
    Ferrero, J-M
    Hardy-Bessard, A-C
    Capitain, O.
    Lortholary, A.
    Salles, B.
    Follana, P.
    Herve, R.
    Deblock, M.
    Dauba, J.
    Atlassi, M.
    Largillier, R.
    CANCER RESEARCH, 2013, 73
  • [40] Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.
    Chen, Li
    Shao Zhimin
    Wang, Zhonghua
    Yang, Wentao
    Jiang, Yizhou
    Zou, Jianjun
    Wu, Jiong
    Di, Genhong
    Liu, Guangyu
    Yu, Keda
    Fan, Lei
    Li, Junjie
    Hou, Yifeng
    Hu, Zhen
    Chen, Canming
    Huang, Xiaoyan
    Cao, Ayong
    Hu, Xin
    Wu, Songyang
    Zhao, Shen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345